{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"150","upperLimit":"643","value":"197"},{"groupId":"OG001","lowerLimit":"1791","upperLimit":"1816","value":"1803"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"Median OS in days. Survival was measured from the time of transplant to the time of death.","dispersionType":"Full Range","groups":[{"description":"First Study Stage: Study Treatment. Visilizumab, Tacrolimus and Methotrexate.","id":"OG000","title":"2 Year Analysis Group"},{"description":"First Study Stage: Study Treatment. Visilizumab, Tacrolimus and Methotrexate.","id":"OG001","title":"5 Year Analysis Group"}],"paramType":"MEDIAN","populationDescription":"Participants who had died by Year 2 and additional participants who had died by Year 5.","reportingStatus":"POSTED","timeFrame":"At 2 years and 5 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"days"}